Topiroxostat Explained

Iupac Name:	4-[5-(4-Pyridinyl)-1''H''-1,2,4-triazol-3-yl]-2-pyridinecarbonitrile
Tradename:	Topiloric, Uriadec
Legal Status:	Approved in Japan
Cas Number:	577778-58-6
Unii:	0J877412JV
Atc Prefix:	None
Pubchem:	5288320
Chemspiderid:	4450517
Smiles:	C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N
Stdinchi:	1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
Stdinchikey:	UBVZQGOVTLIHLH-UHFFFAOYSA-N
C:	13
H:	8
N:	6

Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia.^[1] It was approved for use in Japan in June 2013.^[1]

Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels.^[2]

Notes and References

1. New Drugs FY2013 . Pharmaceuticals and Medical Devices Agency, Japan . dead . https://web.archive.org/web/20140222175138/http://www.pmda.go.jp/english/service/pdf/list/NewdrugsFY2013.pdf . 2014-02-22 .
2. Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, Yamamoto T, Hara S . 6 . Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout . Clinical and Experimental Nephrology . 18 . 6 . 876–84 . December 2014 . 24448692 . 4271138 . 10.1007/s10157-014-0935-8 .